Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 9/20 | 0.57 |
| ▸ | PPARG | P37231 | 1/20 | 0.56 |
| ▸ | DRD2 | P14416 | 7/20 | 0.53 |
| ▸ | DRD3 | P35462 | 6/20 | 0.53 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.51 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.51 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7244085 | 0.89 | PPARG (0.60) | DRD4PPARGDRD2DRD3ADRA1D | |
| SCHEMBL7252088 | 0.88 | PPARG (0.59) | DRD4PPARGDRD2DRD3ADRA1D | |
| SCHEMBL7256938 | 0.86 | PPARG (0.58) | DRD4PPARGDRD2DRD3ADRA1D | |
| SCHEMBL7256394 | 0.86 | DRD4 (0.58) | DRD4PPARGDRD2DRD3ADRA1D | |
| SCHEMBL7250601 | 0.85 | PPARG (0.56) | DRD4PPARGDRD2DRD3ADRA1D | |
| Hydrochloric Acid SCHEMBL7252051 | 0.85 | DRD4 (0.57) | DRD4PPARGDRD2DRD3ADRA1D | |
| SCHEMBL7251464 | 0.85 | PPARG (0.56) | DRD4PPARGDRD2DRD3ADRA1D | |
| SCHEMBL7256249 | 0.85 | PPARG (0.56) | DRD4PPARGDRD2DRD3ADRA1D | |
| SCHEMBL7256547 | 0.85 | PPARG (0.56) | DRD4PPARGDRD2DRD3ADRA1D | |
| Hydrochloric Acid SCHEMBL7253613 | 0.84 | PPARG (0.55) | DRD4PPARGDRD2DRD3ADRA1D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | ASAHI-KASEI KABUSHIKI KAISHA (JP) | 2003-02-27 | — | — | US | claimed |
| EP-1238973-A1 | NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS | Asahi Kasei Kabushiki Kaisha (JP) | 2002-09-11 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030040538-A1 | Novel substituted tricyclic compounds | CPT1A, CBR1, NR1H3 | DRD4 471/4885PPARG 332/4885DRD2 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.